MILPITAS, Calif. -
Nov. 18, 2020 -
PRLog -- SARS-CoV-2 has a ~30 kb genome that encodes 29 proteins, including 4 structural proteins used in virion assembly, namely the Envelope (E), Membrane (M), Spike (S) and Nucleocapsid (N) proteins. The N protein is a RNA-binding protein that maintains the viral genomic RNA in a conformation required for viral RNA transcription and replication. The N protein amino-terminal contains the RNAbinding Domain, a potential structural target for novel antiviral drugs. The N protein is a highly immunogenic antigen, with specific anti-N protein antibodies detected in patient serum 5-10 days following infection.
BioVision's SARS-CoV-2 Nucleocapsid IgG ELISA Kit is an enzyme-linked immunosorbent assay intended for identifying the immune response to SARS-CoV-2 infection. The assay uses the nucleocapsid protein as a bait to capture anti-SARS-CoV-
2 antibodies in diluted plasma or serum samples. Subsequent reaction with an enzyme-labeled anti-human-IgG conjugate and a colorimetric substrate generates color, which is proportional to the amount of anti-N antibodies. The presence of anti-SARS-CoV-
2 N antibodies (IgG) is determined by comparing the absorbance (OD450 nm) reading of the sample to the OD450 nm reading of the negative control serum. A positive reaction suggests prior SARS-CoV-2 infection. Positive control serum containing a recombinant human monoclonal anti-SARS-CoV-
2 N antibody is included in the kit for validation. The assay is a quick, easy and accurate method of indicating recent or prior SARS-CoV-2 infection that does not require collection or handling of infectious virus. This kit is a valuable tool to study the COVID-19 epidemiology, prevalence and morbidity.
Figures: (a) Detection of Anti-SARS-CoV-
2 Nucleocapsid IgG antibodies in serum samples (dilution 1:300). COVID-19 patient samples were obtained from individuals that had a positive test for SARS-CoV-2 viral RNA by RT-PCR from nasopharyngeal swab specimen. All patient serum samples were collected at least 14 days following the initial onset of symptoms and 9-20 days following PCR confirmation of infection. Healthy serum was donor-pooled off-the-clot serum obtained from healthy individuals prior to the COVID-19 pandemic. The response from Negative Control Serum was used to determine the cutoff for positivity (indicated by the dashed line). (b) Serial dilutions of COVID-19 patient sera versus healthy serum. Calculated AUC values for COVID-19 patient samples were 5.96-, 3.22-, 18.65- and 17.81-fold greater than that of pre-pandemic healthy serum, respectively. Data presented are mean ± SD of triplicate or greater wells.
For more information on this ELISA kit cat#E4903 Visit:
https://www.biovision.com/sars-cov-2-nucleocapsid-igg-eli...
